Constructive Bio ^Partner

Constructive Bio is a synthetic biology company that specializes in genome writing and genetic code reprogramming. Founded in 2022, the company emerged from research at the MRC Laboratory of Molecular Biology. It focuses on rewriting entire genomes and reprogramming translation systems to incorporate non-canonical amino acids, which allows for the creation of innovative therapeutics and sustainable biomaterials.

The company offers advanced technologies such as whole genome writing for constructing synthetic bacterial genomes and engineered translation systems that enable the incorporation of multiple non-canonical amino acids into proteins. Constructive Bio's products include virus-resistant biofactories capable of producing biopolymers and pharmaceuticals, as well as programmable biomolecules designed with precision. With a demonstrated ability to synthesize complex molecules at commercial scales, the company targets applications in therapeutics, biomaterials, and industrial biomanufacturing.

Constructive Bio is led by a team with over 20 years of expertise in synthetic biology and has secured $58 million in Series A financing to support its development and commercial scaling efforts. The company aims to partner with industries in pharmaceuticals, materials science, and specialty chemicals to promote sustainable production methods.